Table 2.

Detailed data coding information.

Data Category	Data Captured
Bibliographic information	• Authors • Year of publication • Journal • Title • Reference information • Study URL
Study type (evidence stream)	• Human in vivo epidemiological studies • Animal in vivo (including experimental and observational whole animal studies • In vitro/ex vivo (includes mechanistic studies in humans and other species) • In silico • Review papers
Exposure type	Data are collected on individual PFASs and listed in Supplementary Table 5. Studies which measure effects of mixtures of PFASs or the total sum of PFASs are indicated as such.
Health outcomes	Outcomes include biomarkers indicative of relating to chronic inflammation (KCC6) or immunosuppression (KCC7). Applicability of these outcomes will be based on the presence of relevant biomarkers or other measures of effects according to the classifications below. Assays or other detection method used to identify or measure the specified biomarker(s) will be recorded.
	Chronic inflammation-related biomarkers		Immunosuppression-related biomarkers
	F0B7	Pro-/anti-inflammatory cytokines	F0B7	Innate immunity-related biomarkers: i.e. impairment of the complement system, Natural Killer (NK) cells, etc.
	F0B7	Serum proteins/compounds related to inflammatory conditions
			F0B7	Humoral immunity-related biomarkers: immunoglobulins, vaccine antibody titers, B-cell subtypes
	F0B7	Cellular biomarkers: myeloid-cell infiltration or cell number changes
			F0B7	Cell-mediated immunity-related biomarkers: T-cell subtypes (CD4+/CD8+), chemokines
	F0B7	Intracellular biomarkers: i.e. NLRP3
Human in vivo evidence stream	All human studies were considered for review regardless of population location, sex, etc. Endpoint description: Human in vivo endpoints based on biomarkers or other measures of effect will be broadly categorized as pertaining to inflammation or immunotoxicity. Weighted evidence score is the highest pursuant to Section 2.6.
Animal in vivo evidence stream	Species: species of animal subjects for in vivo studies will be classified within mammalian or non-mammalian sub-groups
	Mammalian		Non-mammalian
	F0B7	African green monkey	F0B7	Atlantic cod
			F0B7	Carp
	F0B7	Baikal seals	F0B7	Chicken
	F0B7	Bottlenose dolphin	F0B7	Chicken embryos
			F0B7	Crabs
	F0B7	Dogs	F0B7	Frogs
	F0B7	East Greenland ringed seals	F0B7	Green mussels
			F0B7	Japanese medaka
	F0B7	Lambs (premature, adults)	F0B7	Japanese quail
			F0B7	Lizards
			F0B7	Manila clam
	F0B7	Macaque	F0B7	Marine medaka
	F0B7	Mice	F0B7	Nematodes
	F0B7	Pigs (neonates, adults)	F0B7	Perch
			F0B7	Rare minnows
	F0B7	Rats	F0B7	Sea turtles
	F0B7	Rabbits	F0B7	Striped bass
	F0B7	Swine	F0B7	Tadpoles
	F0B7	Walruses	F0B7	Thicklip grey mullet
			F0B7	Tonguefish
			F0B7	White-tailed eagle
			F0B7	Zebrafish (embryos, larvae, adults)
	Endpoint description: Animal in vivo study endpoints based on biomarkers or other measures of effect will be broadly categorized as pertaining to chronic inflammation, immunosuppression, or both. Weighted evidence score is high pursuant to Section 2.6.
In vitro/ex vivo evidence stream(s)			Cell species: cell species will be classified as mammalian or non-mammalian sub-groups
			Mammalian
			F0B7	Bottlenose dolphin
			F0B7	Baikal seals
			F0B7	Human
			F0B7	Mice
			F0B7	Murine (unspecified)
			F0B7	Rabbits
			F0B7	Rats
			Non-mammalian
			F0B7	Zebrafish (embryos)
Cell type: Any and all cell types from the above species were considered for review. Endpoint description: Human and animal in vitro study endpoints based on biomarkers or other measures of effect will be broadly categorized as pertaining to chronic inflammation, immunosuppression, or both. Weighted evidence score is low pursuant to Section 2.6.
In silico evidence stream	Endpoint description: In silico study endpoints based on biomarkers or other measures of effect will be broadly categorized as pertaining to chronic inflammation, immunosuppression, or both.
Review evidence stream	Endpoint description: Review studies are not classified as providing evidence to chronic inflammation or immunosuppression endpoints.